Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma

Treatment of metastatic urothelial carcinoma (mUC) after failure with platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) remains controversial. To explore the role of subsequent systemic therapy, medical records from 436 patients who were consecutively treated with chemotherapy for...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Joohyun, Sung, Hyun Hwan, Jeong, Byong Chang, Park, Se Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405748/
https://www.ncbi.nlm.nih.gov/pubmed/36009553
http://dx.doi.org/10.3390/biomedicines10082005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405748/
https://www.ncbi.nlm.nih.gov/pubmed/36009553
http://dx.doi.org/10.3390/biomedicines10082005

Ejemplares similares